DENAVERINE AVZ

Benefits

• rapid therapeutic effect - after 10-15 minutes.

• relaxes cervical smooth muscles

• promotes the elasticity of the birth canal

• has analgesic, anticonvulsant, antipyretic and sedative effects

• reduces the risks of injury to the birth canal in cows and prevents the loss of calves during calving

• helps to reduce the incidence of postpartum diseases in cows and promotes rapid recovery of animals after calving

Composition and pharmacological properties.

1 ml of Denaverine AVZ contains 40 mg of denaverine hydrochloride as active ingredient, as well as benzyl alcohol, propylene glycol, water for injection as excipients.
Denaverine AVZ belongs to the pharmacotherapeutic group of vegetotropic agents.
The denaverine hydrochloride which is a component of the product belongs to the group of beta-blockers, which has a relaxing effect on the smooth muscles of the cervix and helps to increase the elasticity of the birth canal. In this case, the drug blocks individual receptors of the uterus, thereby enhancing the effect of endogenous oxytocin and contractility of the smooth muscles of the uterus. Denaverine hydrochloride has analgesic, anticonvulsant, antipyretic and sedative effects.
Denaverine hydrochloride is rapidly metabolized in the liver and is completely eliminated from the body within 3-5 hours. The therapeutic effect of denaverine hydrochloride develops 10-15 minutes after subcutaneous or intramuscular administration to cows. Muscle relaxation lasts up to several hours, and the analgesic effect persists up to 1.5 hours.                                                                                                                                        
According to the extent of exposure, Denaverine AVZ belongs to the low-risk products (hazard class 4 according to GOST 12.1.007). it has no sensitizing, embryotoxic, teratogenic or mutagenic effects.

Indications

Denaverine AVZ is prescribed to dogs and cattle; for obstetric care in heifers and cows; in narrow cervix and for stimulation of labor; in abnormal fetal position or abnormal development; to limit the risk of injury to the birth canal during fetotomy (Cephalopelvic Disproportion, incorrect positions, various fetal deformities, big twin fetuses).

Contraindications.

Do not use Denaverine AVZ during the early stage of labor, with a closed cervix. 

Posology and method of administration

Cattle: intramuscularly or subcutaneously at following doses:

- heifers: milk-producing breeds – 5.0 ml (200 mg/animal)

 meat-producing breeds – 10.0 ml (400 mg/animal);

cows – 10.0 ml (400 mg/animal);

In dogs Denaverine AVZ is administered intramuscularly or subcutaneously at following doses:

- < 10 kg – 0.5 ml (20 mg/animal);

- 11 to 20 kg – 1.0 ml (40 mg/animal);

- ≥20 kg – 1.5 ml (60 mg /animal).

Side effects.

When Danaverine AVZ is used in accordance with this instructions, the risk of side effects and complications in animals is low. In case of allergic reaction, discontinue treatment with the drug product and, if necessary, start antihistamines and symptomatic therapy. Signs of overdose have not been established. 

Special warnings.

It is not recommended to use with other drugs except for oxytocin. Specific effects after first administration and withdrawal have not been established. The slaughter of animals for meat and the use of livestock products for food after administration of Denaverine AVZ are allowed without restriction.